Daclizumab
CCR4 antagonist 2
HF51116
MIF-IN-2
NRP1 antagonist 1
(6E)-1,7-Bis(4-hydroxyphenyl)-6-hepten-3-one
MIF-IN-5
Glofitamab
Cibisatamab
Etokimab
Isoandrographolide
Rafutrombopag (tautomerism)
CXCR2 antagonist 4
Teplizumab
Pinatuzumab
Nemolizumab
Anifrolumab
Gevokizumab
Uliledlimab
Relatlimab